Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

23.97 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64
Open 23.97
Bid (Size) 23.05 (20)
Ask (Size) 24.79 (1)
Prev. Close 23.97
Today's Range 23.97 - 23.97
52wk Range 18.18 - 27.80
Shares Outstanding 311,989,661
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under which Exelixis will, upon the future closing of the asset purchase and subject to... 
From Business Wire News Releases
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
Bristol Myers Squibb Reports First Quarter Financial Results for 2021 
From Business Wire News Releases

Performance

YTD
+16.76%
+16.76%
1 Month
+2.09%
+2.09%
3 Month
+4.76%
+4.76%
6 Month
+6.11%
+6.11%
1 Year
-5.22%
-5.22%

More News

Read More
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
From Business Wire News Releases
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
From Business Wire News Releases
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
From Business Wire News Releases
Analysts Forecast 22% Upside For The Holdings of FBT
Tags ETFs
From ETF Channel
Exelixis Larger Than S&P 500 Component APA
Tags Stocks
From Market News Video
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcin
From Business Wire News Releases
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanc
From Business Wire News Releases
Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK
Tags Benzinga IPSEY GSK
From Benzinga
3 Top Biotech Picks to Buy and Hold for the Next 10 Years
Tags Market News CRSP EXEL
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.